^
    BIOMARKER:

    FGFR1 expression

    i
    Other names: FGFR1, BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM, Fibroblast growth factor receptor 1
    Entrez ID:
    2260
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors (NCT05369286)
    Phase 1
    Maxinovel Pty., Ltd.
    Recruiting
    Last update posted :
    05/11/2022
    Initiation :
    04/11/2022
    Primary completion :
    05/31/2023
    Completion :
    08/31/2023
    FGFR1OP2
    |
    FGFR1 expression
    |
    Tuoyi (toripalimab) • Max-40279
    Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (ROGABREAST)
    Phase 1
    Fundacion CRIS de Investigación para Vencer el ...
    Recruiting
    Last update posted :
    02/09/2022
    Initiation :
    11/25/2020
    Primary completion :
    02/03/2023
    Completion :
    02/03/2023
    HER-2 • FGFR1
    |
    HER-2 negative • FGFR1 expression
    |
    Ibrance (palbociclib) • fulvestrant • rogaratinib (BAY 1163877)
    Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) (SAKK 19/18)
    Phase 2
    Swiss Group for Clinical Cancer Research
    Active, not recruiting
    Last update posted :
    01/21/2022
    Initiation :
    07/25/2019
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    CD4
    |
    FGFR1 expression
    |
    rogaratinib (BAY 1163877)
    Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression (NCT04040725)
    Phase 2
    Dana-Farber Cancer Institute
    Withdrawn
    Last update posted :
    12/17/2019
    Initiation :
    11/27/2019
    Primary completion :
    11/27/2019
    Completion :
    11/27/2019
    ALB
    |
    FGFR1 expression
    |
    rogaratinib (BAY 1163877)
    Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling (NCT01868022)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    08/19/2019
    Initiation :
    10/09/2013
    Primary completion :
    10/24/2017
    Completion :
    10/24/2017
    FGF2
    |
    FGFR1 amplification • FGFR1 expression
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • FP-1039
    Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" (TARGET)
    Phase 1/2
    Assistance Publique - Hôpitaux de Paris
    Completed
    Last update posted :
    05/29/2019
    Initiation :
    09/01/2015
    Primary completion :
    09/01/2017
    Completion :
    10/01/2018
    FGFR • TACC3 • TACC1
    |
    FGFR fusion • FGFR1 expression • FGFR1 fusion • FGFR3 fusion • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion
    |
    ABSK091
    Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors (NCT02592785)
    Phase 1
    Bayer
    Completed
    Last update posted :
    04/18/2018
    Initiation :
    12/15/2015
    Primary completion :
    02/05/2017
    Completion :
    12/06/2017
    FGFR1
    |
    FGFR3 mutation • FGFR1 expression • FGFR expression
    |
    rogaratinib (BAY 1163877)